Zantac 75 sales reach $46 mil. in second quarter; OTC Tagamet sales $23 mil. worldwide.
This article was originally published in The Tan Sheet
Executive Summary
ZANTAC 75 SECOND QUARTER SALES REACH $46 MIL. in the U.S., and the heartburn remedy has established a "strong number two position" in the OTC H2 antagonist market with a 35% share, Warner-Lambert said July 22. J&J/Merck's Pepcid AC continues as the category leader. Zantac 75 was introduced in the U.S. in late April 1996, and the company recently announced plans to launch the product in Canada, Australia and other European countries ("The Tan Sheet" April 21, p. 10)
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.